Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation.
about
Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Bortezomib-Containing Multimod ...... after Kidney Transplantation.
@en
Bortezomib-Containing Multimod ...... after Kidney Transplantation.
@nl
type
label
Bortezomib-Containing Multimod ...... after Kidney Transplantation.
@en
Bortezomib-Containing Multimod ...... after Kidney Transplantation.
@nl
prefLabel
Bortezomib-Containing Multimod ...... after Kidney Transplantation.
@en
Bortezomib-Containing Multimod ...... after Kidney Transplantation.
@nl
P2860
P50
P1476
Bortezomib-Containing Multimod ...... s after Kidney Transplantation
@en
P2093
Francesco Pisani
P2860
P304
P356
10.3349/YMJ.2017.58.3.679
P577
2017-05-01T00:00:00Z